A Phase 2 Study of LY2835219 for Patients with Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

Investigator: Hope Rugo, MD
Sponsor: Eli Lilly and Company

Location(s): United States


The purpose of this study is to evaluate treatment with the investigational drug LY2835219 in women with previously treated metastatic breast cancer that is positive for hormone receptors (such as receptors for estrogen and progesterone) and negative for the HER2 protein. Researchers will also observe the effect of LY2835219 on patients’ pain symptoms and their quality of life.

LY2835219 is designed to inhibit cancer growth by blocking cyclin-dependent kinases (CDK), enzymes which cancer cells need to grow and divide. It is taken orally (by mouth).